Protocol B and high-throughput selection
WDL technology couples the boundless natural diversity with directed synthetic biology innovation. The company invented a proprietary process, Protocol B™, in addition to numerous other high-throughput selection techniques for the isolation, and cultivation of microbiome-derived Clostridia, which has resulted in large, diverse and novel strain libraries.
Clostridia is a long known but less understood class of bacteria, with promising implications for nutrition and health thanks to ground-breaking studies and emerging applications in microbiome science. Hundreds to thousands of Clostridia strains can be isolated and cultivated in a matter of days via Protocol B and from diverse physiological and environmental samples. Many strains are previously “unculturable” and most are yet identified, exhibiting characteristics that render them as beneficial platforms for synthetic biology and animal and human gut health.
WDL has advanced synthetic biology tools specific for Clostridia, such as advanced plasmid and chromosomal based gene expression systems, gene knockout and knock-in editing, genome scale modeling, and proteomics and metabolomics platforms. The combination of natural diversity and synthetic biology tools allows us to harness awesome phenotypic diversity of these organisms to make bulk and commodity chemicals, specialty chemicals and advanced nutrition products.